CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (GAN-CAR).
This study, called GAN-CAR, is for adults having major heart surgery who are at risk of getting a serious infection called Cytomegalovirus (CMV). It's a common virus, but it can cause significant issues after big operations. Researchers want to see if giving certain medications (Ganciclovir or Valganciclovir) can prevent this infection from flaring up and help patients recover faster and more smoothly. The study will look at how many days patients have a 'good outcome' – meaning they are alive, out of intensive care, not needing strong antibiotics or breathing machines, and without serious side effects. They will compare these medicines against a dummy medicine (placebo) to see if they truly make a difference in patient recovery after heart surgery.
De un vistazo
¿De qué trata este estudio?
Imagine you're having a big heart operation. Your body is working hard to recover, and sometimes, a very common virus called Cytomegalovirus (CMV) can cause trouble when your immune system is a bit weaker. Most people carry CMV without even knowing it, but after major surgery, it can sometimes become active and make recovery much harder.
This study, called GAN-CAR, is designed to find out if using specific antiviral medicines, Ganciclovir or Valganciclovir, can stop this CMV virus from causing problems after major heart surgery. They want to prevent the virus from becoming active in people who are at a higher risk of complications. Researchers will compare these active drugs to a 'dummy' medicine (placebo) to see if they genuinely improve how well patients recover.
Ultimately, the goal is to help patients have better outcomes after their heart surgery. This means getting out of the intensive care unit sooner, not needing powerful antibiotics or help with breathing, and avoiding severe problems. By understanding if these preventative medicines work, doctors can make better choices to help future heart surgery patients recover more safely and comfortably.
Puntos clave
- This study aims to prevent serious virus infections (CMV) after major heart surgery.
- It tests if specific antiviral medications improve recovery compared to a dummy treatment.
- Participation is for adults having major heart surgery who are at higher risk for CMV complications.
- The main goal is to see how many days patients have a good recovery during the first 30 days.
- You will be randomly assigned to receive either the active drug or a placebo.
¿Quién puede ser elegible?
This study is looking for adults aged 18 or older. It's open to both men and women who are having major heart surgery.
You would be considered for the study if you are someone who is generally healthy, but also known to be at a higher risk of developing problems from a common virus called CMV after your operation. The doctors running the study will check if you meet all the specific health requirements to make sure the study is safe and suitable for you.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Eres un adulto de 18 años o más?
- Are you about to have major heart surgery?
- Have doctors identified you as being at higher risk for CMV complications after surgery?
- Are you generally healthy enough to participate in a clinical trial?
¿En qué consiste la participación?
If you decide to take part, you would be randomly assigned to receive either the active study medication (Ganciclovir or Valganciclovir, usually as tablets or a liquid) or a placebo (a dummy treatment with no active medicine, given as a liquid). This is done "double-blind," meaning neither you nor your doctor will know which one you are receiving.
The main part of the study involves daily check-ups for 30 days after your surgery to see how you are recovering. Doctors will monitor if you're out of intensive care, if you need certain medications, or if you experience any side effects. There will also be some blood tests to check your immune system and the virus levels, which will happen at the start, at 14 days, and again at 30 days. The total duration of active follow-up for the main goals of the study is 30 days.
Riesgos y beneficios potenciales
Ubicaciones (1)
- —No verificadoEspaña
Preguntas comunes
What is CMV?
CMV (Cytomegalovirus) is a very common virus that most people have at some point. It usually doesn't cause problems in healthy people, but after major surgery or if your immune system is weak, it can become active and cause illness.
What is 'major heart surgery'?
This refers to significant operations on your heart, like bypass surgery or valve replacement, which are serious procedures that require your body to recover afterwards.
Will I know if I'm getting the real medicine or the dummy one?
No, neither you nor your doctor will know during the study. This is called 'double-blind' and helps ensure the results are fair and unbiased.
¿Cuánto tiempo estaré involucrado en el estudio?
The main part of the study will involve daily monitoring for 30 days after your heart surgery, with some blood tests at specific times within that period.
What is a 'good outcome' in this study?
A 'good outcome' means you are alive, out of the intensive care unit, not needing strong antibiotics or breathing support, and haven't had any serious problems related to the study.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.